{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:24:09Z","timestamp":1789683849980,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2016M3A9E8941331"],"award-info":[{"award-number":["NRF-2016M3A9E8941331"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00280-017-3353-2","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T12:57:33Z","timestamp":1496926653000},"page":"209-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients"],"prefix":"10.1007","volume":"80","author":[{"given":"Bum Jun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaewon","family":"Hyung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Joon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Wan","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Koo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-hong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungwoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heung-Moon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"3353_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"3353_CR2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471\u20131474","journal-title":"Ann Surg Oncol"},{"key":"3353_CR3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281","journal-title":"N Engl J Med"},{"key":"3353_CR4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103:469\u2013474","journal-title":"Br J Cancer"},{"key":"3353_CR5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","volume":"25","author":"JW Valle","year":"2014","unstructured":"Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J, Okusaka T (2014) Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 25:391\u2013398","journal-title":"Ann Oncol"},{"key":"3353_CR6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4143\/crt.2014.308","volume":"47","author":"JO Park","year":"2015","unstructured":"Park JO, Oh DY, Hsu C, Chen JS, Chen LT, Orlando M, Kim JS, Lim HY (2015) Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review. Cancer Res Treat 47:343\u2013361","journal-title":"Cancer Res Treat"},{"key":"3353_CR7","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1002\/cncr.24472","volume":"115","author":"I Park","year":"2009","unstructured":"Park I, Lee JL, Ryu MH, Kim TW, Sook Lee S, Hyun Park D, Soo Lee S, Wan Seo D, Koo Lee S, Kim MH (2009) Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer 115:4148\u20134155","journal-title":"Cancer"},{"key":"3353_CR8","first-page":"428","volume":"5","author":"RD Peixoto","year":"2014","unstructured":"Peixoto RD, Renouf D, Lim H (2014) A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol 5:428\u2013432","journal-title":"J Gastrointest Oncol"},{"key":"3353_CR9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdv483","volume":"27","author":"J Bridgewater","year":"2016","unstructured":"Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, Knox J, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, McNamara MG, Valle JW (2016) Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol 27:134\u2013140","journal-title":"Ann Oncol"},{"key":"3353_CR10","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, Hiraoka N, Ojima H, Shimada K, Okusaka T, Kosuge T, Miyagawa S, Shibata T (2015) Genomic spectra of biliary tract cancer. Nat Genet 47:1003\u20131010","journal-title":"Nat Genet"},{"key":"3353_CR11","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","volume":"122","author":"M Javle","year":"2016","unstructured":"Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J (2016) Biliary cancer: utility of next-generation sequencing for clinical management. Cancer 122:3838\u20133847","journal-title":"Cancer"},{"key":"3353_CR12","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejca.2012.11.024","volume":"49","author":"J Bridgewater","year":"2013","unstructured":"Bridgewater J, Palmer D, Cunningham D, Iveson T, Gillmore R, Waters J, Harrison M, Wasan H, Corrie P, Valle J (2013) Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer 49:1511","journal-title":"Eur J Cancer"},{"key":"3353_CR13","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","volume":"25","author":"A Lamarca","year":"2014","unstructured":"Lamarca A, Hubner RA, Ryder WD, Valle JW (2014) Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 25:2328\u20132338","journal-title":"Ann Oncol"},{"key":"3353_CR14","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1002\/cncr.29471","volume":"121","author":"B Brieau","year":"2015","unstructured":"Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, Lecomte T, Coriat R, Bachet J-B, Claudez P, Zaanan A, Soibinet P, Desrame J, Thirot-Bidault A, Trouilloud I, Mary F, Marthey L, Taieb J, Cacheux W, Li\u00e8vre A (2015) Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Ent\u00e9rologues Oncologues. Cancer 121:3290\u20133297","journal-title":"Cancer"},{"key":"3353_CR15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejca.2012.08.003","volume":"49","author":"T Walter","year":"2013","unstructured":"Walter T, Horgan AM, McNamara M, McKeever L, Min T, Hedley D, Serra S, Krzyzanowska MK, Chen E, Mackay H, Feld R, Moore M, Knox JJ (2013) Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 49:329\u2013335","journal-title":"Eur J Cancer"},{"key":"3353_CR16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/bjc.2016.446","volume":"116","author":"BJ Kim","year":"2017","unstructured":"Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, Ryoo BY, Chang HM (2017) Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer 116:561\u2013567","journal-title":"Br J Cancer"},{"key":"3353_CR17","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D (2016) ESMO Guidelines Committee. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v28\u2013v37","journal-title":"Ann Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3353-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T10:35:22Z","timestamp":1498041322000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3353-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["3353"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3353-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]}}}